Biopharma | May 01, 2026
Laurus Labs FY26 revenue rises 23% to Rs 6,813 Crore; EBITDA surges 64%
Strong CDMO growth, improved product mix and operational leverage drive profitability expansion
Strong CDMO growth, improved product mix and operational leverage drive profitability expansion
The Danish biotech company confirmed the global study will begin in the second half of 2026
The partnership integrates BD’s ZebraSci, a device-agnostic testing platform, with Suttons Creek’s expertise in combination product development and systems integration
Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
The agreement could rise to $900 million if key commercial milestones are met
CPHI India from 23–25 November 2026 at Yashobhoomi (India International Convention and Expo Centre), while PMEC India from 24–26 November 2026 at India Expo Mart
Collaboration to accelerate mRNA neoantigen therapy development for colorectal and pancreatic cancers using advanced immunology and dark genome insights
The company doses first patient in US study of Deraphan, as Dolby Ventures joins €53M Series B to support neuropsychiatric innovation
Former Novo Nordisk and Pharmanovia executive to lead next growth phase in NAD diagnostics and personalised health innovation
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
